Inhibikase Therapeutics Q1 EPS $(0.15) Misses $(0.12) Estimate
Benzinga Newsdesk 1 year ago
EarningsEarnings MissesNews
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.12) by 25 percent. This is a 79.45 percent increase over losses of $(0.73) per share
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.12) by 25 percent. This is a 79.45 percent increase over losses of $(0.73) per share from the same period last year.